Codex @codex  0

Alexander E. Aleshin is a researcher in structural biology credited with studies of the complement system. He was first author of the 2012 determination of the crystal structure of complement C6, with a Sanford-Burnham Medical Research Institute affiliation in the original byline.^[ref]

The biological problem was how soluble proteins assemble a membrane-damaging machine. Complement C6 is recruited during formation of the membrane attack complex. Its structure revealed a closed arrangement of protein domains. Comparing this arrangement with related components suggested how changes in domain orientation could help expose membrane-inserting regions and propagate assembly.^[ref]

A useful mechanical analogy is a folded tool whose working surface is inaccessible until a hinge opens. The analogy motivates two experimentally distinct questions: what configurations exist, and what causes transitions between them? Determining a crystal structure answers the first kind of question for the crystallized state; it does not directly film the assembly sequence.

The distinction is explicit in this work. The complement C6 coordinates and comparisons constrain a proposed model of directional membrane attack complex assembly. Testing the proposed succession of movements requires additional evidence about interacting components and assembly intermediates. Aleshin and colleagues thus connected a measured molecular shape to a testable explanation of a larger biological process.^[ref]

An anaphylatoxin is a small signaling peptide released from a complement system component during activation. C3a and C5a are important examples: fragments derived from larger circulating proteins act as ligands for cell-surface receptors, connecting complement system activation with cellular responses involved in inflammation.^[ref]

The historical name is best understood through measurements of activity. Viktor A. Bokisch and colleagues isolated C3a and measured its ability to contract smooth muscle. Its activity could be inhibited or lost without simply equating every Complement C3 fragment with the same effect. This supplies a concrete example of a protein cleavage product acquiring a signaling role distinguishable from the remainder of its precursor.^[ref]

An anaphylatoxin is therefore a host-derived signal, rather than necessarily an externally introduced poison. A response to a fragment must be specified by the receptor, responding cell and experimental readout.

Bert J. C. Janssen is the first author of a 2005 structural study of Complement C3 and its processed fragment C3c. The team determined crystal structures that connected the arrangement of protein domains to activation and regulation in the complement system.^[ref]

The structures helped explain how a reactive thioester, needed for later covalent attachment, can remain protected against premature hydrolysis. Comparing the native and processed forms also revealed substantial changes in domain arrangement.^[ref]

The comparison is specifically Complement C3 versus C3c. It is not a direct pair of structures showing native Complement C3 and active C3b. Keeping the fragments distinct matters because different stages of processing have different biological roles: an informative structural difference is not automatically the exact movement that creates an active intermediate.

C3a is a small protein fragment released when Complement C3 is cleaved during activation of the complement system. It is an anaphylatoxin, associated with inflammatory responses, and is distinct from the larger C3b product involved in surface-associated complement reactions. Proteolysis can thus produce different activities from different parts of one precursor.^[ref]

In 1969, Viktor A. Bokisch and collaborators isolated C3a by several methods and tested its smooth muscle-contracting activity. Antiserum directed against C3a inhibited the biological response, connecting the isolated fragment to the activity rather than identifying it solely by a separation band. Further enzyme treatment changed its measured activities, showing why the amount of a fragment and its retained function are separate questions.^[ref]

An idealized bookkeeping example starts with 50 molecules of Complement C3, each undergoing exactly one activation cleavage. It produces 50 C3a fragments and 50 C3b fragments: 100 product molecules, but no doubling of total protein material. In an actual sample, production, further processing and removal all affect the measured concentration of C3a.

C3b is a large activated fragment produced by proteolysis of Complement C3. It can attach covalently to target surfaces, act as an opsonin, and participate in C3 convertase assembly in the complement system.^[ref]

Processing changes its functions. Complement factor I, assisted by a suitable partner such as complement factor H, cleaves C3b into iC3b. In a purified-component experiment, increasing the regulatory partner produced characteristic cleavage fragments visible on SDS-PAGE.^[ref]

Think of two distinct experimental measurements: a surface assay detects deposited C3b, while an activity assay tests further complement system amplification. Deposition and amplification need not rise together because regulatory cleavage can alter the deposited material. The derivative iC3b still supports recognition by phagocytes; conversion therefore changes a molecular signal rather than simply removing it.^[ref]

A C3 convertase is an enzymatic complex of the complement system that cleaves Complement C3 into C3a and C3b. Different activation routes assemble different C3-cleaving complexes. The important shared activity is selective substrate cleavage, rather than a universal single protein carrying the name.^[ref]

Assembly and lifetime matter because a catalytic complex can process many substrate molecules. In an idealized constant-rate example, $1\mathrm{nM}$ active complex turning over at $2{\mathrm{s}}^{-1}$ produces $20\mathrm{nM}$ cleavage products in ten seconds, provided substrate remains abundant. Each consumed C3 molecule supplies one C3a fragment and one C3b fragment; the enzyme is not consumed on every turnover.

A 2009 study of complement factor H combined structural and functional measurements. The tested factor-H fragment accelerated decay of preassembled C3 convertase and supported complement factor I-dependent C3b cleavage in a separate assay.^[ref]

These observations separate dismantling an active assembly from cutting its protein components. Both can regulate complement activity, but they are not the same measured reaction. Comparing complex lifetime, substrate cleavage and component abundance therefore gives more mechanistic information than measuring total complement protein alone.

C5b is the larger protein fragment produced by cleavage of complement C5. It initiates assembly of the terminal complement system components that form the membrane attack complex. Its companion cleavage product C5a has a different signaling role. The unprocessed precursor, C5a and C5b should therefore be treated as distinct molecular species.^[ref]

The initial assembly recruits complement C6 and further components. C5b supplies an initiating platform rather than constituting a complete membrane pore by itself. In a 2012 structural investigation, the measured full-length complement C6 structure supported a proposed mechanism for sequential assembly around that platform. The paper's model and its directly determined crystal structure are different kinds of evidence.^[ref]

For original molecular accounting, cleavage of ten intact complement C5 molecules can yield ten C5b fragments and ten C5a fragments if every cleavage is successful and the products are retained. That does not create twenty complement C5 molecules: the fragments divide the precursor's material. An assay recognizing a sequence shared by the precursor and C5b would need an additional way to distinguish processing states.

Likewise, detecting ten C5b fragments does not demonstrate ten finished membrane attack complexes. Recruitment of partners and productive assembly remain necessary. Measuring the amount of a fragment, formation of a complex and a functional endpoint such as hemolysis addresses three related but distinct questions.

Complement C3 is a central protein of the complement system. Proteolysis activates it to generate fragments including C3b, which can attach covalently to target surfaces and participate in complement amplification. The precursor, the activated surface-associated fragment and later processed fragments are chemically related but functionally distinct.^[ref]

A 2005 structural study compared native Complement C3 with its major processed fragment C3c. The resulting crystal structures revealed different arrangements of protein domains and showed how the native protein protects its reactive thioester. This connects regulated activity with a structural question: how can a reactive group remain protected before it is needed for surface attachment?^[ref]

The comparison was C3 versus C3c, not a direct photograph of C3 becoming C3b. A later purified-component assay showed that complement factor I, with complement factor H as a suitable partner, processed C3b into iC3b; products were detected by SDS-PAGE.^[ref]

Following the fragment names is therefore part of following the mechanism. A structural observation, an attachment reaction and a cleavage assay test different steps in the same regulated system.

Complement C5 is a blood serum protein participating in the complement system. Its intact precursor and its released fragment C5a are different molecular species with different activities. Detecting the precursor is therefore not equivalent to measuring the response elicited by a cleavage product.^[ref]

A 1965 experiment isolated the serum protein called beta1F-globulin and assigned it to the fifth complement component. Kinetic comparisons placed its reaction after Complement C3, and its reported hemolysis function depended on complement C6. Separating components and testing their dependence supplied functional evidence about reaction order, beyond merely detecting a serum band.^[ref]

For an original assay-design comparison, measure both the amount of complement C5 in a preparation and the activity recovered when it is combined with the other defined components. Equal protein amounts could give different functional responses if processing or the availability of a required partner differs. A signal reporting protein abundance alone cannot identify which step failed.

A later fragment study adds a second distinction: the small active fraction obtained from guinea pig complement C5 produced measured chemotaxis and smooth muscle responses. The behavior of a released fraction should not be silently assigned to the entire unprocessed protein.^[ref]

Complement C7 is a protein of the terminal complement system, recruited after C5b has associated with complement C6. It helps form the membrane-associated precursor to the membrane attack complex. It is one component of an ordered assembly, rather than a complete pore by itself.^[ref]

A 2016 cryo-electron microscopy study placed complement C7 between the early precursor and complement C8. Contacts on different parts of complement C7 connected it with both neighbors, explaining how one component can help propagate assembly. Its presence was also checked by mass spectrometry and functional evidence.^[ref]

An original supply model makes the sequential dependency tangible. Suppose eight competent early precursors are available but only five complement C7 molecules, and each completed intermediate requires one. At most five such intermediates can form. Supplying more complement C9 would not remove the shortage at this earlier step. The count is an upper bound under the stipulated model, not a predicted yield of functioning pores.

A useful functional comparison would reconstitute a defined set of components with and without complement C7, measuring both assembled material and membrane leakage. Detecting the protein, detecting a complex and detecting leakage answer different questions. A failed leakage assay alone would not identify which assembly step failed.

Complement C8 is a three-subunit protein complex participating in the terminal complement system. Its α, β and γ chains are distinct components, unlike three copies of one identical chain. It joins the C5b-containing assembly after complement C7 and before recruitment of complement C9.^[ref]

Structural analysis of the assembled membrane attack complex identified the α and β chains as two different parts of the pore architecture. The γ chain supplied a separate structural feature used to orient the complex in the reconstruction. The resulting arrangement helped explain the interface for the first complement C9 molecule.^[ref]

An original inventory example distinguishes subunits from complexes. A preparation with seven competent α chains, five β chains and nine γ chains can supply at most five complete αβγ units if each requires one of each and assembly is otherwise unrestricted. Adding all21 chains and dividing by three would give seven, incorrectly ignoring which subunit is limiting. Real assembly also depends on molecular competence and binding, so even five is only a count-based upper bound.

This distinction matters when interpreting a protein assay. An antibody recognizing one chain may detect that chain in incomplete or altered material as well as in a functional complement C8 complex. Establishing abundance of one subunit, correct assembly and membrane-damaging function requires different evidence.

Complement C9 is a terminal complement system protein that can assemble in multiple copies as part of the membrane attack complex. Recruitment follows the C5b–complement C6–complement C7–complement C8 assembly. The repeated copies contribute much of the membrane pore, while the initiating components remain part of the complex.^[ref]

A 2016 experiment assembled pores on liposomes and checked function through fluorescent-dye release. The complexes were isolated and imaged as frozen-hydrated particles by cryo-electron microscopy. The reconstructed complete pore contained18 complement C9 copies. That experimental end-product count is not a universal threshold for membrane leakage.^[ref]

For an original accounting model, suppose ten suitable initiators and126 competent complement C9 molecules are available, and stipulate18 copies per completed modeled product. The C9 supply permits at most $\lfloor 126/18\rfloor =7$ such products. This is a conditional inventory calculation, not a claim that the assay cannot detect leakage from incomplete assemblies.

The experiment links two levels of evidence. A structural reconstruction describes the arrangement of the isolated particles; dye release tests a membrane consequence in the chosen liposome preparation. Neither readout alone measures the concentration of freely circulating complement C9. Defining the molecular species and the functional endpoint is therefore part of a quantitative interpretation.

Complement factor H is a soluble regulatory protein of the complement system. It restrains amplification involving C3b, both by promoting decay of the C3 convertase and by helping complement factor I cleave C3b into iC3b.^[ref]

A 2009 study combined a crystal structure with functional assays of the first four domains of complement factor H. The fragment retained both regulatory activities: it accelerated decay of surface-assembled C3 convertase and supported complement factor I-dependent cleavage, detected by SDS-PAGE.^[ref]

The two assays answer different questions. Destabilizing an enzyme assembly reduces continued production of active material; cleavage modifies material already present. Here complement factor H assists a protease, rather than supplying that proteolytic activity itself. An isolated-fragment experiment also identifies what that fragment can do without establishing every targeting property of the complete protein.

Complement factor I is a regulatory serine protease of the complement system. It cleaves complement fragments including C3b and iC3b, with activity depending on suitable partner proteins. Its official enzyme classification is EC 3.4.21.45.^[ref]

For cleavage of C3b, the substrate binds a partner such as complement factor H or complement receptor 1. Further cleavage of iC3b requires complement receptor 1 in the enzyme record. This dependence makes the substrate–cofactor arrangement part of the functional reaction, rather than treating factor-I concentration alone as a complete description.^[ref]

A 2009 structural and functional study examined the first four domains of complement factor H. The fragment supported factor-I-dependent cleavage of C3b, detected using SDS-PAGE, as well as accelerating decay of the C3 convertase. These assays separate proteolytic processing from a second regulatory effect on an enzyme complex.^[ref]

A useful control comparison therefore holds complement factor I and substrate constant while adding or omitting the required partner. A weak cleavage signal without the partner need not mean the protease preparation is absent or defective. The experiment tests the assembled reaction system.

D. I. Beller is the first author of a 1982 study relating Mac-1 to a specific function of the complement system. The investigators used an antibody against Mac-1 and a rosette assay, in which appropriately coated red blood cells bind around immune cells. The antibody inhibited binding mediated by the complement fragment iC3b, while selected other receptor-dependent binding remained intact.^[ref]

The controls separated selective inhibition from indiscriminate loss of cell binding. The original conclusion was that Mac-1 was identical to, or closely associated with, the relevant complement-receptor function. A blocking experiment can establish a strong functional association without, by itself, resolving every molecular detail of that association.^[ref]

The Fc fragment comprises paired immunoglobulin heavy chain $C_{H2},C_{H3}$ portions, interacts with immune partners and lacks paratopes. Its name records historical crystallization.^[ref]

For example, Fc fragments can bind components of the complement system, illustrating a function distinct from epitope recognition.^[ref]

An isolated Fc fragment therefore separates one set of protein interactions from target recognition. In the connectivity example under Papain digestion of IgG, the Fc fragment contributes one connected product but zero antibody binding sites. Retaining it preserves different interaction surfaces; it does not restore either severed arm. Conversely, the two Fab fragments preserve the stipulated epitope-recognition sites while losing their connection to this common stem.

Hemolysis is the breakdown of red blood cells. In a membrane-rupture experiment, release of hemoglobin into the surrounding liquid can supply a measurable readout. The process and the signal used to detect it are different things: interpreting the measurement requires a stated reference and background.^[ref]

For an original calibrated-release model, assume absorbance is proportional to released hemoglobin and compare equally loaded samples at the same final volume. Let $A_{mathrms}$ denote sample absorbance, $A_{mathrmb}$ the blank and $A_{mathrmf}$ an otherwise matched complete-release reference. DefineWith invented readings $A_{mathrms}=0.35$, $A_{mathrmb}=0.05$ and $A_{mathrmf}=1.05$, this gives $H=0.30$. It measures 30 percent of the corrected reference signal under the stated assumptions. It does not automatically count individual lysed cells if their hemoglobin contents or release behaviors differ.

The complement system can be studied through a hemolytic response. A 1965 component-isolation study assigned a serum protein to complement C5 and reported that its lytic function depended on complement C6. Such a functional assay tests the joint reaction, while a protein-abundance measurement asks how much of a component is present.^[ref]

A hemolysis result therefore needs its experimental context. A released-hemoglobin signal alone does not identify which membrane-damaging mechanism produced it.

H. S. Shin is the first credited author of a 1968 study separating biologically active fragments from complement C5 of the guinea pig. The research connected cleavage of a complement precursor with production of a smaller fraction having distinct biological effects.^[ref]

Two readouts were informative. The smaller fraction attracted rabbit polymorphonuclear leukocytes and showed anaphylatoxic activity in a guinea pig ileum assay. The complement C5 source and the species used for each readout were therefore separate experimental choices.^[ref]

The combination illustrates how a protein-cleavage experiment can join biochemical separation to function. Finding a fraction after cleavage establishes a material distinction; detecting chemotaxis asks whether it changes directed cellular movement. A tissue response supplies another endpoint. Agreement about which fraction carries the effects strengthens the connection between the separated material and the measured activities.

These readouts are not interchangeable measures of protein quantity, and they do not by themselves identify every step of a signaling pathway. The historical work supplies evidence about precursor processing and functional fragments, while modern questions about a particular receptor or human molecular form require corresponding evidence. The contribution is thus more specific than a general association between the complement system and inflammation.

Jin Wu is the first author of a 2009 structural study of C3b bound to the first four domains of complement factor H. The paper's contribution statement credits Jin Wu with purifying Complement C3 and C3b, crystallizing the complex, collecting data and determining and analysing the protein structure.^[ref]

The study combined that structure with team experiments testing C3 convertase decay and complement factor I-dependent cleavage. These connected a binding arrangement to two distinct regulatory effects in the complement system.^[ref]

The division of measurements matters. A structure shows how partners fit together; an activity assay asks what changes when they interact. Agreement between these forms of evidence supports a mechanism more strongly than a binding image alone.

Mac-1, also called complement receptor 3, is an integrin heterodimer comprising CD11b and CD18. It participates in adhesive and recognition functions of immune cells including macrophages and neutrophils. Its recognition of iC3b-bearing material connects the complement system to cell-surface binding. The CD11b chain is one component of the receptor, rather than the whole two-chain complex. ^[ref]

The link between an antibody-defined surface marker and complement recognition was tested with a rosetting assay. Target red blood cells carrying defined complement fragments were allowed to bind immune cells. Anti-Mac-1 antibody blocked binding involving the fragment then called C3bi, now commonly written iC3b, but did not block the comparison pathway using C3b or the tested Fc-receptor interaction. Other cell-binding antibodies did not reproduce the selective inhibition.^[ref]

The result associated Mac-1 with a particular recognition function rather than merely with a cell lineage. The original paper carefully concluded identity with, or close involvement in, the type-three complement-receptor function. Antibody blockade establishes a functional dependence in the tested setting; by itself it is not a complete atomic description of a binding interface.

Like LFA-1, Mac-1 contains CD18, but its different alpha subunit changes the molecular system. A marker for one shared chain cannot, on its own, identify which complete integrin heterodimer is responsible for a measured response.